US Stock Futures Signal Higher Start On Wall Street

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Pre-open moversUS stock futures traded higher in early pre-market trade. The U.S. Treasury monthly budget report for February will be released at 2:00 p.m. ET. Futures for the Dow Jones Industrial Average surged 58 points to 17,724.00, while the Standard & Poor's 500 index futures rose 8.40 points to 2,050.30. Futures for the Nasdaq 100 index climbed 14 points to 4,345.25.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

A Peek Into Global Markets European markets were mostly higher today, with the Spanish Ibex Index rising 1.17%, STOXX Europe 600 Index surging 1.44% and German DAX 30 index gaining 1.86%. French CAC 40 Index climbed 1.91% and London's FTSE 100 Index fell 0.24%.In Asian markets, Japan's Nikkei Stock Average rose 0.31%, Hong Kong's Hang Seng Index dropped 0.75%, China's Shanghai Composite Index gained 0.15% and India's BSE Sensex fell 0.18%.Broker RecommendationAnalysts at JP Morgan upgraded

Credit Suisse Group AG (NYSE: CS) from Underweight to Overweight. Credit Suisse shares rose 6.67% to close at $25.11 yesterday.Breaking news

The ExOne Company (NASDAQ: XONE) announced today that it has appointed Hans J. Sack to serve as President of the Company effective March 16, 2015. To read the full news, click here.
Heat Biologics (NASDAQ: HTBX) announced Tuesday, the pricing of an underwritten public offering of 1,640,000 shares of common stock at a public offering price of $6.50 per share. To read the full news, click here.
Exelis (NYSE: XLS) has been awarded a multimillion dollar contract from Airbus to produce center wing box struts for the A350-1000 aircraft. To read the full news, click here.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company's anti-PD-1 therapy, pembrolizumab, which is marketed in the U.S. under the name KEYTRUDA®, is the first treatment to be accepted under the U.K.'s new Early Access to Medicines Scheme (EAMS). To read the full news, click here.